2010-2011
The following is a description of a study from one of the many researchers that our organization has funded.
Beyond TNF: A Newly Discovered Cytokine may provide new target for RA Therapy
Christopher Benedict, Ph.D.
La Jolla Institute for Allergy and Immunology
San Diego, California
Analyzing the contribution of the LIGHT-HVEM-BTLA system in autoimmune arthritis
Tumor necrosis factor (TNF) is a cytokine produced by the body’s immune cells that fuels the process of inflammation in rheumatoid arthritis (RA). Blocking TNF is the best current treatment for RA. Dr. Benedict is studying a newly discovered cytokine network that is a close relative of TNF and may contribute to the initiation and/or severity of RA. Using mouse models, he hopes to generate information about neutralizing this new network that could lead to new clinical treatments for RA.
Dr. Benedict is this year’s Eng Tan Scholar, so honored for his innovative approach to studying inflammatory arthritis.
You may return to the list of research that we have funded.
